[Treatment of Ewing's sarcoma in children and adolescents: a cooperative study of the German society of pediatric oncology (author's transl)].
The German Society of Pediatric Oncology designed a cooperative study (CESS 81) to improve the patients outlook with primary Ewing's sarcoma. Patients are randomized whether or not to receive bleomycin in addition to conventional four drug regimen including vincristine, adriamycin, cyclophosphamide and actinomycin D. For local therapy radiotherapy or surgery can be used alternatively. Patients who received radiotherapy for local control, and show measurable shrinking of the primary tumor under chemotherapy, are randomized to receive 4600 rad or 6000 rad for local control. Patients' accrual is expected to be about 100 patients over 3 years.
D001761:Bleomycin / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis; D011879:Radiotherapy Dosage; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide
Ewing-Sarkom bei Kindern und Jugendlichen: Planung einer kooperativen Therapiestudie der Gesellschaft für Pädiatrische Onkologie (CESS 81).